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Background: Squamous cell carcinoma of the head and neck (SCCHN) are highly invasive tumours with frequent
local and distant recurrence. Metastasis formation requires degradation of the extracellular matrix, which is fulfilled
by membrane-associated proteases such as the urokinase plasminogen activator (uPA). WX-UK1 is a competitive
active site inhibitor of the protease function of uPA that impairs on the capacity of tumour cells to invade in vitro.
Methods: In the present study, effects of combinations of WX-UK1 with matrix metalloprotease inhibitors (MMP,
galardin®) and cyclooxygenase-2 (COX-2, celecoxib®) inhibitors on tumour cell proliferation, invasion, and
angiogenesis induction were evaluated. Matrigel invasion chambers and a spheroid co-cultivation model with
human fibroblast served to determine the invasive potential of both FaDu (SCCHN) and HeLa (cervical carcinoma)
cells, each treated with combinations of Celecoxib®, Galardin®, and WX-UK1.
Results: Blocking of single protease systems resulted in a significant 50% reduction of tumour cell invasion using
WX-UK1, while the triple combination was even more effective with 80% reduction of invasion. Additionally, a
sprouting assay with HUVEC was used to test the anti-angiogenetic potential of the triple combination, resulting in
a 40% decrease in the sprouting rate.
Conclusions: A combined approach targeting different families of proteases and cyclooxygenases represents a
promising adjuvant therapy.
Background
Squamous cell carcinoma of the head and neck
(SCCHN) are aggressive tumours, which are still asso-
ciated with poor prognosis despite improvements in sur-
gical and radiotherapeutic techniques [1]. SCCHNs
exhibit highly invasive growth, aggressive metastasis for-
mation, and early recurrence [1]. In order to metasta-
sise, tumour cells utilize a complex set of molecular
mechanisms [2]. Migration through surrounding tissue
is achieved upon the degradation of the extracellular
matrix (ECM) by both, membrane-fixed and soluble
proteases. In this respect, matrix metalloproteases
(MMP) and the urokinase-type plasminogen-activator
system (uPA), which is responsible for the conversion of
plasminogen into plasmin, are of major importance. The
activity of MMPs and uPA fosters cell migration, angio-
genesis and metastasis [3,4]. Tumours greater than 1.5
mm
3 in size are strictly dependent on intimate contacts
to blood vessels or otherwise become necrotic [5]. Neo-
angiogenesis is provided via the production of growth
factors such as basic fibroblast growth factor (bFGF)
and vascular endothelial growth factor (VEGF), which
attract endothelial cells into the tumour tissue to enable
tumour progression. In turn, de novo formed vessels
strengthen tumour invasion and metastasis through the
production of MMP 2 and 9 and uPA, which further
degrade ECM. The in vivo anti-metastatic and anti-pro-
liferative activity of the synthetic uPA inhibitor WK-
UK1 has been demonstrated in various animal tumour
models. WX-UK1 is a serine protease inhibitor that
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any medium, provided the original work is properly cited.inhibits protease upon attachment to the active center of
the enzyme, resulting in a reduction of tumour expan-
sion [6]. As the plasminogen activator system plays a
role in coagulation, thrombotic vessel occlusion could
be a risk during therapy, but these side-effects were
neither observed in vivo nor in vitro [7]. MMPs are
zinc-bound enzymes that degrade ECM and, particularly
MMP 3, 2 and 9, play a role in tumour expansion, inva-
sion and metastasis. According to the frequent over-
expression of MMPs in malignant tumours and to the
correlation with a highly aggressive phenotype and poor
prognosis [8,9], inhibition of MMPs has provided a sig-
nificant increase in the survival rate in clinical trials
[10]. Combinatorial inhibition of MMPs and the plasmi-
nogen activator system using siRNA approaches likewise
revealed efficient with a 60% and 90% down-regulation
of invasion and angiogenesis, respectively [11,12].
Another group of anti-angiogenic active pharmaceuti-
cal agents comprises non-steroidal anti-inflammatory
drugs. In vitro studies have suggested a potential of
cyclooxigenase-2 (COX-2) inhibitors to block angiogen-
esis and reduce the growth of colon, head and neck, and
skin tumours [13,14]. These therapy forms have fewer
side effects in comparison to conventional treatment
regimens such as chemotherapy and/or radiotherapy
most probably owing to the fact that healthy persons
utilize angiogenesis primarily to circumvent chronic
inflammation diseases and during the female menstrual
cycle. Importantly, resistance did not emerge in mouse
models of fibrosarcoma, Lewis lung carcinoma and mel-
anoma, after repeated in vivo treatment with the antian-
giogenic agent endostatin [15,16]. The over-expression
of components of the uPa system, pro-angiogenic cyto-
kines such as bFGF and VEGF, and MMPs in malignant
tumours in comparison to normal tissue, correlates with
a poor prognosis and a higher recurrence rate [8].
Numerous synthetic protease inhibitors have been tested
in clinical trials. Our own group described a 50% inhibi-
tion of tumour cell invasion using the serine protease inhi-
bitor WK-UK1 in vitro [17], however a wide clinical
application as a monotherapy has not been put into prac-
tice yet. Previous expertise disclosed that only multimodal
therapy strategies take into account the plethora of
mechanisms underlying tumour progression and are
hence indispensible. Thus, a combination of inhibitors
that address different aspects of tumour progression and
metastasis formation is a promising concept [18,19].
In this study, the serine protease inhibitor WK-UK1,
the MMP inhibitor Galardin® and the selective COX-2
inhibitor Celecoxib® have been tested as a combinatorial
treatment with chemical compounds against carcinoma
cells. Treatment of carcinoma cells resulted in a signifi-
cantly improved inhibition of invasion as compared to
monotherapy with WX-UK1 and sprouting of the
endothelial cells was inhibited by about 40%, too. Thus,
our results suggest that the combination of three classes




FaDu (SCCHN), HeLa (cervical carcinoma), and human
primary skin fibroblasts (generated from skin biopsies
from healthy volunteer donors) were cultured in standard
Dulbecco’s Modified Eagle Medium (DMEM) containing
10% fetal bovine serum (FCS), with 1% penicillin-strepto-
mycin and 1% sodium pyruvate, in a humidified incuba-
tor at 37°C at 5% CO2 to confluence. HUVEC were
freshly isolated from human umbilical veins of newborns
by collagenase digestion, as described previously [20].
HUVECs were grown in monolayers, were harvested by
centrifugation and amplified at 37°C in endothelial cell
growth medium (EBM2, Cambrex, Verviers, Belgium). In
all our experiments, only the first three passages of each
HUVEC primary culture were used. Single-cell suspen-
sions were performed by mild enzymatic dissociation
using trypsin/EDTA (0.05%/0.02% w/v) solution in PBS.
MTT assay
Cellular metabolism was assessed in a standard MTT
conversion assay as described previously [21]. Briefly,
FaDu, HeLa, fibroblasts and HUVE cells (3 × 10
3 cells/
well) were plated in 96-well plates and analyzed at the
time points indicated.
Immunostaining of chamber slides
For immunohistochemical staining, chamber slide cul-
tures (Quadriperm, Sigma Aldrich) were generated from
human epitheloid carcinoma cell lines FaDu and HeLa
using 4-5 × 10
5 cells per slide. Immunodetection of
MMP 1, 2, 9 (IgG mouse anti human, 1:100; R&D Sys-
tem, Wiesbaden, Germany), MMP 3 (IgG goat anti
h u m a n ,1 : 1 0 0 ;R & DS y s t e m ,W i e s b a d e n ,G e r m a n y ) ,
COX-2 (IgG rabbit anti human, Medac, Wedel, Ger-
many) and VEGF (IgG goat anti human, 1:100; R&D
System, Wiesbaden, Germany) in chamber slides was
performed using the standard ABC method as explained
below. The specific staining was visualized in red and
slides were counterstained with hematoxilin, giving blue
colored nuclei.
Negative control staining for immunohistochemistry
was performed in the absence of primary antibody.
Spheroid co-culture model
A spheroid co-culture model was established according
to the method described by Kunz-Shughart et al. [22],
in order to assess the invasive potential of FaDu and
HeLa cell lines into fibroblast spheroids. In order to
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suspensions were added pre-formed fibroblast spheroids,
which were generated on 96-well plates (100 μl/well)
coated with 1% agarose. For this purpose, primary fibro-
blasts (1 × 10
4) were plated separately in 100 μl DMEM
(10% FCS) per well. After 24 hours, single cell suspen-
sions (FaDu 3 × 10
3,H e L a8×1 0
3) were incubated for
further 3 days, renewing the medium every 48 hours.
WX-UK1, Celecoxib® and Galardin® were added to cul-
ture media every 48 hours in the concentrations
described below, as single agents or in double and triple
combinations. Spheroid specimens were embedded in
tissue-tek (Sakura Finetek, Torrance, CA), shock-frozen
in liquid nitrogen and stored at -20°C. This process was
carried out in 3 independent experiments, each resulting
in 6-8 single co-culture samples.
Immunohistochemistry (double staining)
Multiple cryosections (4 μm) of each spheroid co-cul-
ture specimen were fixed in acetone (10 min, RT) and
incubated in H2O2 (10 min, RT, 0.03%) to block endo-
genous peroxidase activity. After washing in PBS, slides
were incubated with either EpCAM-specific MAb C215
(1:200, kind gift of Dr. H. Lindhofer, GSF, Munich,
Germany) or the cytokeratin-specific MAb KL1 (1:500;
pan-cytokeratin, reacts with several cytokeratin subtypes;
Coulter-Immunotech Diagnostics, Krefeld, Germany).
The standard ABC kit (Vectastain; Vector, Burlingame,
CA) was used to detect for an Antigen-antibody reac-
tion. The peroxidase reaction was developed with AEC
as a chromogen (Sigma, St. Louis, MO), resulting in red
staining. The additional prolyl-4-hydroxylase-specific
MAb 5B5 (1:100; Dako, Glostrup, Denmark) was visua-
lized by the APAAP method. After incubation with
MAb 5B5, sections were incubated with goat antimouse
IgG (1:25) and mouse APAAP complex (1:50; both from
Dako). Finally, staining was performed with fast blue BB
salt (Sigma), and sections were mounted in Kaiser’s
glycerol gelatin for subsequent analysis. Negative control
staining for immunohistochemistry was performed in
the absence of primary antibody.
Evaluation of immunostaining
The invasive potential of tumour cells into pre-formed
fibroblast spheroids was quantified as follows: quadrants
invaded by tumour cells were counted by two experi-
enced investigators independently, and divided by all
counted quadrants of the spheroid. Invasion proportion
was calculated as the proportion of fibroblast quadrants
invaded by tumour cells relative to control-treated cells.
Matrigel invasion assay
The invasion potential of cells was assessed in a matrigel
invasion chamber using the BD BioCoat Matrigel
Invasion Chamber (Becton Dickinson Biosciences, Bed-
ford, MA). Briefly, 750 μl of NIH-3T3 conditioned fibro-
blast supernatant or alternatively from primary human
fibroblasts derived from a hypopharynx carcinoma
(24 hours in serum-free medium) were added to wells of
the companion plate, and a cell suspension containing
2.5 × 10
4 FaDu or HeLa tumour cells in 500 μl medium
(0.1% FCS) was added into inserts for 24 hours, as was
WX-UK1 (Wilex, Munich, Germany) at a concentration
of 1.0 μg/ml, Galardin® (5 M/μl, Calbiochem, Germany),
and Celecoxib® (5 μM/ml, Molekula Nienburg, Weser).
Transmigrating cells were stained with toluidine blue
and counted at a 320-fold magnification by light micro-
scopy. The four quarters of the membrane (0.8 cm
diameter) were counted separately, each corresponding
to one visual field under the microscope, where the
margin containing remaining cells that could not be
r i n s e do u tw a sn o tc o n s i d e red. Three individual
experiments with each cell line were performed.
Migration assay
The migration of cultured FaDu, HeLa and HUVECs in
the absence and presence of inhibitors was assayed by
using transwell chamber with 8 μm pores (Corning
Costa, Cambridge, Ma). Cultured cells were trypsinized
and suspended at a concentration of 1 × 10
6 cells/ml. 100
μl of this suspension was placed on the upper chamber
and treated with or without inhibitors. Conditioned
supernatant of murine NIH-3T3 fibroblast (24 hr in
serum-free medium) was added to wells of the compa-
nion plate as a chemoattractant. The chamber was then
incubated at 37°C for 8 hours, filters were removed, fixed
and stained with toluidine blue, and counted at 320-fold
magnification by light microscopy. The four quarters of
the membrane (0.8 cm diameter) were counted sepa-
rately, each corresponding to one visual field under the
microscope, where the margin containing remaining cells
that could not be rinsed was not considered. Three indi-
vidual experiments with each cell line were performed
allowing the calculation of ratios of Matrigel invasion/
migration capacity.
In vitro angiogenesis assay
HUVEC spheroids, each containing 1000 cells, were gen-
erated over night and embedded into collagen gels. A col-
lagen stock solution was prepared prior to use by mixing
acidic collagen extract of rat tails (equilibrated to 2 mg/
ml, 4°C; 8 vol.) with 10× EBSS (Gibco BRL, Eggenstein,
Germany; 1 vol.) and in approx. 1 volume of 0.1 N
NaOH to adjust the pH to 7.4. This stock solution
(0.5 ml) was mixed with 0.5 ml ECGM basal medium
(PromoCell, Heidelberg, Germany) with 10% FCS, (Bio-
chrom, Berlin, Germany) containing 0.5% (w/v) carboxy-
methylcellulose to prevent sedimentation of spheroids
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50-70 HUVEC spheroids and test substances were added
to the mixture. The spheroid-containing gel was rapidly
transferred into pre-warmed 8 well plates (Ibidi, Munich,
Germany) and allowed to polymerize (1 min). Gels were
incubated at 37°C in 5% CO2 atmosphere at 100%
humidity. After 24 hours in-gel angiogenesis was quanti-
fied for each experimental group by using a light micro-
scope to count the number of capillary-like sprouts of at
least 10 spheroids. Three individual experiments were
performed.
Chemotactic migration assay
Chemotactic migration of cultured HUVEC was assayed
using a Transwell chamber with 8 μm pores (Corning
Costa, Cambridge, MA). Cultured cells, which were
hungered over night, were trypsinized and suspended at
ad e n s i t yo f1×1 0
6 cells/ml, and 100 μl was placed on
the upper chamber. As a chemotactic agent, the lower
chamber was filled with 500 μl of conditioned superna-
tant of treated or untreated tumour cells. The chamber
was incubated at 37°C for 8 hours before removal of fil-
ters, fixation, staining with toluidine blue, and counting
at 320-fold magnification by light microscopy. The 4
quarters of the membrane (0.8 cm diameter) were each
counted separately as each corresponds to one visual
field under the microscope. The margin containing the
remaining cells that could not be rinsed was not consid-
ered. Three individual experiments were performed.
ELISA
Concentrations of bFGF were assessed upon ELISA
according to the manufacturer’s protocol (Human FGF
basic, R&D Systems, Mineapolis, MN, USA).
Statistical evaluation
Significance of experimental data was calculated using a
paired Student’s t-test and the Excel software (Microsoft
Corp., Redmond, WA) or a combination of ANOVA
and Kruskal-Wallace tests. P-values are given when
appropriate in the according figures.
Results
Triple inhibition of uPA, MMPs, and COX-2 decreases the
invasive capacity of tumour cells
Inhibition of the uPA protease system with WX-UK1
displayed excellent results with a 50% rate of inhibition
of tumour cell invasion into matrigel and in a spheroid
co-culture model [17]. Nonetheless, this rate has room
for improvement for example upon combinations of
therapeutics. We chose three mechanisms contributing
to tumour cells invasion and neo-angiogenesis to be
inhibited in a multimodal fashion, i.e. uPA, matrix
metalloproteases, and cyclooxygenase 2. The availability
of targets was assessed in the SCCHN FaDu and in the
cervix HeLa carcinoma cell lines. Expression of COX-2,
MMP1-3 and 9, and VEGF was assessed via immuno-
histochemistry with specific antibodies and revealed
intermediate (COX-2) to high (Figure 1). Expression
patterns of uPA and uPA-R have been displayed in our
former studies and both cell lines revealed positive for
components of the uPA-system [17]. Potential toxic
effects of each compound as a single and multimodal
treatment were assessed in a standard vitality MTT
assay. No significant decrease or increase in cell vitality
was observed upon treatment of FaDu and HeLa cells
with all three compounds (additional file 1).
Next we generated spheroids from primary skin fibroblasts
and incubated pre-formed spheroids with single cell sus-
pensions of FaDu or HeLa cells. Invasion of pre-formed
fibroblast spheroids by single tumour cells was monitored
in cryosections and after staining of tumour cells with
cytokeratin-specific antibodies as described in materials
and methods. The nature of invading cells was further cor-
roborated upon staining for the tumour-associated antigen
EpCAM [23] (data not shown). Untreated FaDu and HeLa
cells were characterised by a strong invasion capacity into
fibroblast spheroids, which was set to 100% for the pur-
pose of comparison (Figure 2). Next, FaDu and HeLa cells
were treated with Celecoxib®, Galardin®,W X - U K 1 ,a n d
combinations thereof, before incubation with fibroblast
spheroids. Celecoxib®, Galardin® displayed no major effect
on tumour cell invasion when applied as single drugs and
at the concentration chosen, while the combination of
both inhibitors resulted in a 30% reduction for FaDu cells
(Figure 2A and 2C). WX-UK1 inhibited tumour cell inva-
sion by 50% and 30% in FaDu and HeLa cells, respectively
(Figure 2A and 2C). However, the most effective inhibition
was achieved with a triple combination of WX-UK1,
Galardin®, and Celecoxib® with 80% and 90% of inhibition
for FaDu and HeLa cells, respectively (Figure 2).
Fibroblast spheroids emulate the tissue surrounding
tumours and metastasis and hence represent a valuable
model for invasion and tissue remodelling. However, in
order to obtain a more direct evidence for the effect of
medication on the invasion capacity of tumour cells,
transmigration experiments with matrigel invasion
chambers were conducted. FaDu and HeLa cells were
treated with WX-UK1 alone or a combination of WX-
UK1, Galardin®, and Celecoxib®, and plated on matrigel
invasion chambers composed of 6-well inlays with 8 μm
pores coated with extracellular matrix (ECM) and
allowed to transmigrate towards murine NIH3T3 fibro-
blasts’ supernatants. As a control, transmigration values
were related to the migration capacity of cells through
inlays lacking the ECM coat. Inhibition of the uPA sys-
tem with WX-UK1 alone resulted in a 55% reduction of
transmigration of FaDu and HeLa cells as compared
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combination yielded an average 90-95% inhibition of
transmigration (Figure 3A and 3B). In order to
strengthen the correlation to the situation in vivo,w e
conducted additional transmigration experiments with
supernatants from human, primary fibroblasts derived
from head and neck carcinoma samples. The results
obtained herewith were similar to experiments per-
formed with NIH3T3 supernatants and corroborated the
efficacy of triple medication on the invasive capacity of
FaDu and HeLa tumour cells (Figure 3C).
COX-2, MMPs, and uPA-system inhibition impacts on neo-
angiogenic potential of tumour cells
The ability of carcinoma cells to attract endothelial cells
in order to generate new vessels is mandatory to sup-
port tumour maintenance and growth. Hence, we first
analysed the effect of WX-UK1, Galardin®,a n d
Figure 1 MMP, COX-2 and VEGF expression. Immunohistochemical detection of MMP 1, 2, 3, 9, COX-2 and VEGF in chamber slides of FaDu
(A) and HeLa cells (B). Shown is one representative experiment out of three.
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cells to produce neo-angiogenic factors such as bFGF.
FaDu and HeLa cells were treated with WX-UK1, Galar-
din®, and Celecoxib® as single drugs and with combina-
tions thereof, and thereafter amounts of bFGF in
supernatants were measured via ELISA. The COX-2
inhibitor Celecoxib® displayed the greatest effects as a
single drug and in combination with WX-UK1 and/or
Galardin® (Figure 4). Triple medication was neither for
FaDu nor for HeLa cells more effective than Celecoxib®
alone, pinpointing that COX-2 inhibition was instru-
mental in the reduction of bFGF release by tumour
cells. Next, human umbilical vein endothelial cells
(HUVEC) were used to monitor the chemoattractant
potential of tumour cells depending on the treatment
with WX-UK1, Galardin®,a n dC e l e c o x i b ®.F a D ua n d
Figure 2 Effects of WXUK-1 (SPI), Celecoxib (COXI), and Galardin (MMPI) on FaDu and HeLa cell invasion capacity.( A) FaDu cells (3000
cells) or (C) HeLa cells (8000) were cultured in absence or presence of single, double or triple combination therapy. Shown is the mean
infiltration of tumour cells with standard deviation into 15-18 pre-formed fibroblast spheroids performed in three independent experiments. (B)
FaDu and (C) HeLa single cells (brown staining) and human primary skin fibroblast spheroids (1 × 10
4 cells, blue staining) were visualised by
immunohistochemistry with antibodies against cytokeratines and MAb 5B5 in kryosections at day three of co-culture in the absence (left
sections) and in the presence of inhibitors (right sections).
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Page 6 of 12Figure 3 Effects of WX-UK1, Galaradin®, and Celecoxib® on matrigel transmigration of tumour cells.( A) Shown are mean of invasion/
migration ratios with standard deviation from three independent experiments. FaDu and HeLa cells were treated with WK-UK1® (SPI), triple
combination of WX-UK1, Galaradin®, and Celecoxib®, or kept untreated (control). (B) Representative images of FaDu and HeLa cells after matrigel
transmigration in the absence (left panels) or presence of WX-UK1, Galaradin®, and Celecoxib® are shown (right panels). (C) Same experiments as
in (A) with supernatants from primary fibroblasts derived from hypopharynx carcinoma samples. Shown are mean of invasion/migration ratios
with standard deviation from three independent experiments.
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ple combination of WX-UK1, Galardin®, and Celecoxib®.
Conditioned supernatants of these cells thereafter served
as chemoattractants in the lower chamber of a transwell
migration assay for HUVEC. Treatment of FaDu and
HeLa cells resulted in a reduction of attraction of
HUVEC by 40% in average (Figure 5).
In addition to their ability to migrate, endothelial cells
imperatively need to form sprouts so as to generate new
vessels. Spheroids of HUVEC were grown in vitro and
transferred into collagen gel along with a triple combi-
nation of WX-UK1, Galardin®, and Celecoxib® or diluent
only. After 24 hrs, the angiogenic potential of HUVEC
spheroids was monitored as the ability to generate
sprouts in vitro in collagen gel. HUVEC spheroids dis-
played a very low intrinsic capacity of sprouting in the
absence of tumour cell supernatants (Figure 6, first col-
umn and picture). Addition of FaDu or HeLa condi-
tioned supernatant to HUVEC spheroids induced the
formation of 30 sprouts in average per spheroid. This
capacity of tumour cell supernatants was almost
abolished upon pre-treatment of cells with WX-UK1,
Galardin®,a n dC e l e c o x i b ® (Figure 6). Hence, the neo-
angiogenic potential of FaDu and HeLa cells was
strongly reduced upon inhibition of COX-2, MMPs, and
the uPA-system.
Discussion
One of the major drawbacks in anti-tumour therapy
results from occult tumour cells that remain after sur-
gery and/or radiochemotherapy. Owing to their invasion
ability, these cells may lead to the formation of locore-
gional and/or distant metastases, which are associated
with dramatically reduced overall survival times of
tumour patients. The tumour cells are referred to as the
origin of minimal residual disease (mrd) [24]. Whether
MRD cells are equivalent to or bear similar properties
as cancer-initiating cells [25], also referred to as cancer
stem cells, is as to now unknown and under current
investigation. Whatever the nature of MRD cells is, they
require replicative, proteolytic, and neo-angiogenic
potential to be the origin of secondary tumours and/or
Figure 4 Amounts of bFGF in supernatants of FaDu and HeLa cells measured via ELISA, treated with WX-UK1, Galardin®, and
Celecoxib® as single drugs and with combinations thereof. The COX-2 inhibitor Celecoxib® displayed the greatest effects as a single drug
and in combination with WX-UK1 and/or Galardin®. Triple medication was neither for FaDu nor for HeLa cells more effective than Celecoxib®
alone, pinpointing that COX-2 inhibition was instrumental in the reduction of bFGF release by tumour cells.
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peutic approaches promise to provide highest benefit for
the afflicted patient. The extent of invasive capacity of
tumour cells is very complex since different proteolytic
cascades, enzymes, and cellular systems play crucial
roles [27,28]. Malignant cells utilize the same arsenal of
proteases to spread and invade as the healthy body for
(patho)-physiological process e ss u c ha st i s s u er e m o d e l -
ling, wound healing, traversal of immune cells through
cell layers and embedding of the zygote in the uterine
mucosa.
Accordingly, tumours hijack the normal control sys-
tem of the proteases and use them for their own pur-
poses. An excessive increase in the uPA system was
shown to associate with tumour progression and metas-
tasis formation [29-31], and an increase in MMPs is
associated with degradation of ECM leading to the
release of growth factors like bFGF and VEGF. This
overexpression of MMP results is a predictor of a poor
patient prognosis [32]. In addition to invasion and tissue
remodelling, neo-angiogenesis is yet another major fac-
tor that influences tumour progression and metastasis
formation [33]. Both, MMPs and COX-2 inhibitors have
been well documented to have potent anti-angiogenetic
effects [13,14,34,35]. As tumour biology is a complex
mechanism, an effective therapy must consequently con-
sist of a combination of various substances that inhibit
different systems. In line with these findings, siRNA-
mediated down-regulation of MMPs and members of
the uPA system revealed instrumental. Targeting of
those proteases in a combinatorial fashion inhibited
invasion and angiogenesis [12]. Although novel concepts
Figure 5 Chemotactic potential of FaDu and HeLa cells on HUVEC. Using the Boyden chamber assay the chemotaxis of HUVEC was
assessed using supernatant of FaDu (A) and HeLa (B) cells kept untreated (left columns) or treated with the triple combination (right columns p
< 0.01). Shown are mean percentages of migration with standard deviation of three independent experiments.
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Page 9 of 12Figure 6 Effects of WX-UK1 (SPI), Celecoxib® (COXI), and Galardin® (MMPI) on the sprouting capacity of HUVEC spheroids in collagen
gel. Shown are the mean numbers of sprouts of HUVEC with standard deviation from 15-20 individual spheroids performed in three
independent experiments. HUVEC were incubated with conditioned supernatants of FaDu (A) and HeLa cells (B). Lower panels show
representative images of HUVEC spheroids.
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underway [11], alternatives, which e.g. include the use of
chemical compounds as presented herein, are promising
innovations. Furthermore, we expand the spectrum of
malignancies to head and neck as well as cervix carci-
noma lines.
Former studies using the serine protease inhibitor WX-
UK1 were conducted with a spheroid confrontation
model, in which the effects of WX-UK1 on the capacity of
tumour cell spheroids to invaginate and invade fibroblast
spheroids was tested. In average, tumour invasion was
reduced by 50% upon treatment with WX-UK1 [17]. In
the present study, invasion of single carcinoma cells in
fibroblast spheroids was inhibited upon pre-treatment of
tumour cells with combinations of the serine protease
inhibitor WX-UK1, Galardin®, and Celecoxib®.T h i sm o d e l
reflects best the situation of MRD cells in vivo,w h i c h
invade and remodel the surrounding tissue. Interestingly,
significant inhibition using the MMP-inhibitor Galardin®
or the selective COX-2 inhibitor Celecoxib® as single
drugs was not observed and is in discordance with the per-
vading literature [36,37] describing an inhibition of inva-
sion by 40% after Celecoxib® treatment. A possible
explanation for this discrepancy is the use of YD-10B cells,
which might reveal more responsive to Celecoxib® than
FaDu and HeLa cells as used in the present study. Another
study demonstrated that the invasion reduction upon
COX-2 inhibitors also appears to act independently of
COX-2 [38-40], potentially explaining the discrepancy in
inhibition despite similar COX-2 levels. Most importantly,
treatment of tumour cells with the triple combination dis-
played a synergistic effect: inhibition of the invasion of
FaDu and HeLa cells was in any case above 80% and
peaked at 95%. Hence, the usage of WX-UK1, Galardin®,
and Celecoxib® as a combinatorial therapy is conceivable.
The triple therapy has not only ascendancy on inva-
sion but also inhibits angiogenesis. The distribution of
growth factors such as Vascular endothelial growth fac-
tor (VEGF) or basic fibroblast growth factor (bFGF)
advocates the migration of endothelial cells as well as
the sprouting of new blood vessels, allowing the tumour
to establish contact with the blood system and subse-
q u e n t l yi n c r e a s em e t a s t a s i s .I nt h es a m em a n n e r ,t h e
production of bFGF was decreased through the use of
all single, double and triple therapy combinations by 60-
80%, but without an additional or synergistic effect.
These data are in line with Hasegawa et al. [41] and
Basu et al. [42] showing an inhibition of bFGF and
VEGF using a selective COX-2 inhibitor. Treatment of
tumour cells with the triple combination of inhibitors
not only impacted on bFGF release but also displayed
functional effects. The release of chemoattractants by
FaDu and HeLa cells was substantially reduced upon
treatment, and resulted in diminished migratory capacity
of HUVEC towards tumour cell supernatant and
reduced tube formation. Again, these results are in full
accordance with Basu et al., who pointed out that Cele-
coxib reduced the formation of blood vessels [42].
Taken together, the combination of different inhibitors
appears as a promising concept in multimodal tumour
therapy, particularly because tumour cells often develop
resistances against single therapies.
Conclusions
Combinatorial treatment of carcinoma cells with inhibi-
tors of the uPA system (WX-UK1), MMPs (Galardin),
and COX-2 (Celecoxib) is superior to the single treat-
ment with WK-UK1 alone. Triple medication inhibited
the invasive and angiogenic potential of carcinoma cells
by 90% and 70%, respectively. Hence, multimodal ther-
apy involving the presented targets is a promising
approach to treat cancer.
Additional file 1: Effects of chemical inhibitors on cell vitality.T h e
effects of Galardin (MMPI), WX-UK1 (SPI), and COX2 inhibitor (COXI) were
assessed in standard MTT assays at maximal tolerable doses of each
compound and in the combinations indicated. Shown are the mean and
standard deviations of three independent experiments.
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